Stock Research for AGN

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

AGN Stock Chart & Research Data

The AGN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AGN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


AGN Due diligence Resources & Stock Charts

The AGN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View AGN Detailed Price Forecast - CNN Money CNN View AGN Detailed Summary - Google Finance
Yahoo View AGN Detailed Summary - Yahoo! Finance Zacks View AGN Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View AGN Trends & Analysis - Trade-Ideas Barrons View AGN Major Holders - Barrons
NASDAQ View AGN Call Transcripts - NASDAQ Seeking View AGN Breaking News & Analysis - Seeking Alpha
Spotlight View AGN Annual Report - CompanySpotlight.com OTC Report View AGN OTC Short Report - OTCShortReport.com
TradeKing View AGN Fundamentals - TradeKing Charts View AGN SEC Filings - Bar Chart
WSJ View Historical Prices for AGN - The WSJ Morningstar View Performance/Total Return for AGN - Morningstar
MarketWatch View the Analyst Estimates for AGN - MarketWatch CNBC View the Earnings History for AGN - CNBC
StockMarketWatch View the AGN Earnings - StockMarketWatch MacroAxis View AGN Buy or Sell Recommendations - MacroAxis
Bullish View the AGN Bullish Patterns - American Bulls Short Pains View AGN Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View AGN Stock Mentions - StockTwits PennyStocks View AGN Stock Mentions - PennyStockTweets
Twitter View AGN Stock Mentions - Twitter Invest Hub View AGN Investment Forum News - Investor Hub
Yahoo View AGN Stock Mentions - Yahoo! Message Board Seeking Alpha View AGN Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for AGN - SECform4.com Insider Cow View Insider Transactions for AGN - Insider Cow
CNBC View AGN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for AGN - OTC Markets
Yahoo View Insider Transactions for AGN - Yahoo! Finance NASDAQ View Institutional Holdings for AGN - NASDAQ


Stock Charts

FinViz View AGN Stock Insight & Charts - FinViz.com StockCharts View AGN Investment Charts - StockCharts.com
BarChart View AGN Stock Overview & Charts - BarChart Trading View View AGN User Generated Charts - Trading View


Latest Financial News for AGN

Allergan Stock Down Since Q1 Earnings Report: Here's Why
Posted on Wednesday May 23, 2018

Though Allergan (AGN) boasts a solid underlying business, its stock is down. Here we discuss why.


Allergan plc (NYSE:AGN): Has Recent Earnings Growth Beaten Long-Term Trend?
Posted on Tuesday May 22, 2018

After reading Allergan plc’s (NYSE:AGN) most recent earnings announcement (31 March 2018), I found it useful to look back at how the company has performed in the past and compareRead More...


Fifth Third Bancorp and Celgene: Top Losses on May 21
Posted on Tuesday May 22, 2018

The S&P 500’s top losses on May 21 were: Fifth Third Bancorp (FITB) declined 7.9%. Celgene (CELG) declined 4.7%. Symantec (SYMC) declined 2.7%. Allergan (AGN) declined 2.7%. Campbell Soup (CPB) declined 2.3%. Fifth Third Bancorp


Allergan Exercises Option to Acquire Compound from Aptinyx Discovery Platform Under Ongoing Research Collaboration
Posted on Tuesday May 22, 2018

EVANSTON, Ill., May 22, 2018 /PRNewswire/ -- Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced Allergan plc (AGN) has exercised its option to acquire drug candidate AGN-241751, an oral small-molecule N-methyl-D-aspartate (NMDA) receptor modulator. Aptinyx discovered AGN-241751 utilizing its proprietary chemistry platform and the compound was selected for further development by Allergan under its ongoing research collaboration with Aptinyx. Allergan was granted option rights to a limited number of small molecules from the Aptinyx discovery platform under a research collaboration initiated in conjunction with its 2015 acquisition of Naurex, the predecessor company from which Aptinyx and its platform were spun out.


Enter a stock symbol to view the stock details.